VALNEVA chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 4.18
Dividend & YieldN/A€ (N/A)
Beta 0.99
Market capitalization 777.44M
Operating cash flow -149.06M
ESG Scores unknown

Company description

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio1.25
Working Capital-0.34
Return On Equity-0.43
Debt To Equity0.3
Fixed Asset Ratio0.07
Fixed Interest Cover-3.77

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 2.41M 10.24M 94.67M 74.35M
Total Cashflows From Investing Activities -2.92M -10.69M -19.34M -93.12M
Net Borrowings -14.15M -2.61M 26.16M -3.9M
Total Cash From Financing Activities 30.95M -7.7M 21.74M 154.5M
Change To Operating Activities -1k 6.37M 99.76M 134.85M
Issuance Of Stock 49.29M 21k 290k 166.82M
Net Income 3.26M -1.74M -64.39M -73.42M
Change In Cash 43.54M -12.64M 140M 142.29M
Effect Of Exchange Rate -795k 207k -183k 3.96M
Total Cash From Operating Activities 16.31M 5.53M 137.74M 76.9M
Depreciation 2.9M 8.53M 6.31M 10.46M
Change To Account Receivables 4.34M -17.28M -24.02M -21.35M
Other Cashflows From Financing Activities -4.17M -5.11M -4.71M -8.42M
Change To Netincome 2.26M 1.83M 26.12M 40.56M
Capital Expenditures -2.87M -10.5M -18.94M -92.23M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax 3.35M -870k -65.3M -69.98M
Net Income 3.26M -1.74M -64.39M -73.42M
Selling General Administrative 37.86M 42.69M 45.9M 71.61M
Gross Profit 43.3M 35.39M -28.43M -13.12M
Ebit 6.27M 1.18M -55.91M -63.95M
Operating Income 6.27M 1.18M -55.91M -63.95M
Interest Expense -3.79M -2.63M -10.74M -16.96M
Income Tax Expense 88k 874k -909k 3.45M
Total Revenue 113.03M 126.2M 110.32M 348.08M
Cost Of Revenue 69.74M 90.8M 138.76M 361.2M
Total Other Income ExpenseNet -2.92M -2.05M -9.39M -6.03M
Net Income From Continuing Ops 3.26M -1.74M -64.39M -73.42M
Net Income Applicable To Common Shares 3.26M -1.74M -64.39M -73.42M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 86.72M 129.57M 371.74M 646.77M
Total Stockholder Equity 143.19M 135.15M 77.42M 170.58M
Other Current Liabilities 3.45M 9.8M 116.81M 273.37M
Total Assets 229.91M 264.72M 449.16M 817.35M
Common Stock 13.64M 13.64M 13.65M 15.79M
Other Current Assets 10.26M 14.92M 57.83M 71.03M
Retained Earnings -161.56M -178.63M -243.02M -316.49M
Treasury Stock 46.21M 55.23M 61.81M 62.03M
Cash 81.72M 64.44M 204.44M 346.69M
Total Current Liabilities 42.94M 41.3M 175.87M 368.98M
Other Stockholder Equity 47.34M 56.34M 62.71M 62.67M
Property, Plant, and Equipment 38M 69.34M 78.15M 173.83M
Total Current Assets 125.97M 129.16M 308.43M 585.83M
Net Tangible Assets 100.35M 95.29M 43.75M 139.46M
Net Receivables 11.26M 24.03M 19.23M 44.01M
Accounts Payable 9.18M 8.87M 24.9M 16.04M


Insider Transactions

Here are the insider transactions of stock shares related to VALNEVA:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to VALNEVA. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on VALNEVA

Here is the result of two systematic investment strategies applied to VALNEVA. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on VALNEVA

The following chart shows the equity curve of the two systematic investment strategies applied to VALNEVA:

VALNEVA automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 316.63% on the backtest period.

Performance at glance

Performance

316.63 %

Latent gain

5553.58 €

Invested capital

1753.94 €

Annualized return

77.61 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on VALNEVA

This is the result of two momentum investment strategies applied to VALNEVA. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on VALNEVA

The following chart shows all the entries opened by the momentum investment system on VALNEVA:

VALNEVA momentum entries
  • The first momentum investment strategy would give 406.97% of return on VALNEVA. That represents 18314.91€ of latent gain with 4500.33€ of employed capital.
  • The second momentum investment strategy would give 425.38% of return on VALNEVA. That represents 11698.75€ of latent gain with 2750.21€ of employed capital.
Performance at glance (1Q Momentum)

Performance

406.97 %

Latent gain

18314.91 €

Invested capital

4500.33 €

Annualized return

358.47 %
Performance at glance (2Q Momentum)

Performance

425.38 %

Latent gain

11698.75 €

Invested capital

2750.21 €

Annualized return

118.16 %

Momentum equity curve on VALNEVA

The following chart shows the equity curve of the two momentum strategies applied to VALNEVA:

VALNEVA momentum equity

Note: the dividends potentially given by VALNEVA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on VALNEVA

The following chart shows the employed capital evolution of the two momentum strategies on VALNEVA since the beginning:

VALNEVA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on VALNEVA

Buy the dip entry openings on VALNEVA

VALNEVA

The performance achieved by the robo-advisor on VALNEVA is 745.62%. That represents 1867.11$ of latent gain with 250.41€ of employed capital. The following chart shows VALNEVA stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of VALNEVA, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

745.62 %

Latent gain

1867.11 €

Invested capital

250.41 €

Annualized return

358.47 %

Equity curve of the strategy applied to VALNEVA

The following chart shows the result of the investment strategy applied to VALNEVA:

VALNEVA

Note: the dividends potentially given by VALNEVA are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on VALNEVA

The following chart shows the employed capital evolution since the beginning of the investment strategy on VALNEVA:

VALNEVA

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on VALNEVA

In this section, I will compare the three previous investment strategies applied to VALNEVA.

Equity curve comparison on VALNEVA

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

VALNEVA investment strategy comparison

Employed capital comparison on VALNEVA

VALNEVA investment comparison

Performance comparison on VALNEVA

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 316.63% 5553.58€ 1753.94€ 77.61%
Momentum 1 quarter 406.97% 18314.91€ 4500.33€ 105.98%
Momentum 2 quarters 425.38% 11698.75€ 2750.21€ 118.16%
Non-directional 745.62% 1867.11€ 250.41€ 358.47%
Annualized return comparison

Automatic investment

77.61 %

Momentum 1Q

118.16 %

Momentum 2Q

118.16 %

Non-directional

358.47 %

Correlated stocks

Here are the most positively and negatively correlated stocks with VALNEVA:

Positive correlations

Most correlated stocks this year

  • VALNEVA

  • Most correlated stocks last 3 months

  • VALNEVA

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • HEALTHWAY MED

  • Note: The algorithm computes the probability of correlation between VALNEVA and the other stocks. There may be false positives or some missing correlated stocks. If the price of VALNEVA does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name VALNEVA
    Country France
    City Saint-Herblain
    Address 6 rue Alain Bombard
    Phone 33 2 28 07 37 10
    Website valneva.com
    FullTime employees 762
    Industry Biotechnology
    Sector Healthcare
    Exchange XPAR
    Ticker VLA.XPAR
    Market www.euronext.com

    VALNEVA ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown